A Multi Center, Sequential, Open-Label, Multiple-Dose Study of Setrobuvir (STV) Alone and With Co-Administration of Ritonavir-boosted Danoprevir to Evaluate the Safety, Tolerability and Pharmacokinetics of STV, DNV, and Ritonavir (RTV) in Subjects With Mild Hepatic Impairment Compared to Healthy Controls
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2016
At a glance
- Drugs Setrobuvir (Primary) ; Danoprevir; Ritonavir
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Roche
- 03 Nov 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Jan 2013 Planned End Date changed from 1 Aug 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
- 19 Nov 2012 New trial record